News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Announces Global Cell and Gene Therapy Center of Excellence

Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and leveraging experience for sponsors to increase program success

SOUTHBOROUGH, MA – October 22, 2020 – Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Read More

Veristat Launches A Flexible Virtual Clinical Trial Solution

Veristat Enhances Patient-Centricity Offering by Delivering Clinical Trials
Directly to Patients

SOUTHBOROUGH, MA – September 30, 2020 – Veristat, a scientific-minded global clinical research organization (CRO), announced today the launch of a virtual clinical trial solution that is flexible and customizable so that patient interactions can be conducted at the clinical site, remotely at-home, or through a hybrid combination of both strategies.

Read More

Veristat Helps Antibe Therapeutics Complete Their Phase IIB Study During COVID-19

In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. To date, this is one of the largest studies completed in Canada consisting of 360 patients with osteoarthritis (“OA”) of the knee, across 40 clinical sites.   

Read More

Veristat Strengthens Its European Presence with the Acquisition of TCTC

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle

Read More

Veristat Strengthens Its Regulatory Expertise with the Acquisition of Catalyst Regulatory Services

Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors
 Along the Pathway to Market Approval

 

Read More

Veristat Expands Operations into Taiwan

Veristat Expands Operations into Taiwan to Support Growing Client Demand for Clinical Trial, Biostatistics and Programming Excellence in the Region

Opens office in Taipei, Taiwan

 

Read More

Veristat Advances Game-Changing Pain and Inflammation Therapy

Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. 

Read More

Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

 

Read More

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

Read More

Veristat Partners with TRI For Risk-Based Monitoring Technology

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients

 

Read More